je.st
news
Tag: vaginal
Sow vaginal microbiota heritable; can predict reproductive performance
2020-06-02 16:54:00| National Hog Farmer
A novel biomarker measured early and able to predict future performance is an ideal strategy for the selection of high-performing sows.
Tags: performance
predict
reproductive
vaginal
Johnson & Johnson loses vaginal mesh class action
2019-11-21 09:32:42| BBC News | Business | UK Edition
In one of Australia's biggest class actions, a court ruled the firm failed to warn women of the risks.
Tags: action
class
johnson
mesh
J&J destroyed thousands of files on vaginal mesh implants, judge says
2014-02-06 00:42:54| Food - Topix.net
NEW BRUNSWICK - Johnson & Johnson improperly destroyed files about some vaginal-mesh implants and may have to let juries weighing lawsuits over the devices hear evidence about the destruction, a court official said.
Tags: files
says
thousands
mesh
Mercks Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study
2013-11-04 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Immunogenicity non-inferior to GARDASIL for original four HPV types Merck expects to file Biologics License Application with U.S. FDA in 2013 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in the pivotal Phase III efficacy study, its investigational 9-valent HPV vaccine (V503) prevented approximately 97 percent of cervical, vaginal and vulvar pre-cancers caused by HPV types 31, 33, 45, 52, and 58. Language: English Contact: Media:Pamela Eisele, 908-423-5042orImraan Munshi, 215-652-0059orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: in
additional
study
iii
REFILE-UPDATE 2-Jury awards $3.35 mln in vaginal mesh case against J&J
2013-02-25 23:52:26| Biotech - Topix.net
A jury on Monday said Johnson & Johnson should pay a South Dakota woman $3.35 million for failing to adequately warn her doctor of the potential dangers of a vaginal mesh implant made by the company's Ethicon subsidiary, and for misrepresenting the product in brochures.